GKA Blog

Recruiting hard-to-reach respondents: six steps to success

Posted by Adam Irwin on 28/02/19 14:55

 The quality of your participants is paramount to the success of your study. Good participants can be the difference between insightful, in-depth results that fulfil your objectives and fieldwork that just falls a bit flat. Let’s face it - it’s tricky to find terrific respondents these days, even when you’re working with the most generic of target audiences. But add low incidence rate diseases and HCPs who specialise in rare therapy areas into the mix and you’ve got even more work to do. Don’t worry though - it can be done! Here’s our six-step guide on how to recruit hard-to-reach participants so your medical fieldwork recruitment goes smoothly, no matter how strict your criteria.

Read More

Topics: healthcare market research

How the NHS budget has changed

Posted by Adam Irwin on 18/02/19 09:23

 

How the NHS budget has changed over time

When the NHS first began back in 1948, it had a budget of £427 million - which, allowing for inflation, is equal to around £15 billion today. However, in the last few decades, this budget has spiralled to around £124 billion. And whilst funding continues to grow, the NHS never seems to have enough funding to cover its huge growth in costs since its inception 70 years ago.

The NHS never fails to be top of the priority list whenever there’s a general election or a big budget announcement, but despite all the headlines, in reality, few people fully understand how the NHS is really funded, and what on earth politicians mean when they talk about mandate budgets, user changes and growth percentage.

Read More

Topics: commissioning

Who’s who in oncology?

Posted by Adam Irwin on 12/02/19 10:07

Medical oncologists are doctors who diagnose, assess, treat and manage patients with cancer. In the UK, the four most common types of cancer are breast, lung, prostate and bowel - but there are actually more than 200 different types of cancer, which can make it difficult to recruit the right participants for your healthcare fieldwork research.

Read More

From the patient’s perspective… Haemophilia

Posted by Adam Irwin on 12/02/19 09:52

There are an estimated 400,000 people worldwide living with haemophilia, with approximately 6,000 sufferers in the UK alone. Haemophilia is an inherited disorder that affects the body’s ability to clot. Usually, when someone cuts themselves, clotting factors and platelets combine to make the blood stickier and stop the bleeding. However, in haemophiliacs, the bleeding episodes last longer due to abnormal clotting, and bruising and spontaneous bleeding can also occur too. The main problem for haemophiliacs is internal bleeding into joints, muscles and soft tissues, which can cause pain and stiffness and ultimately lead to joint damage. To better our understanding of the patient's perspective when it comes to market research studies, we spoke to someone who recently took part in haemophilia research with GKA.

Read More

Topics: healthcare market research

Who’s who in Breast Cancer

Posted by Adam Irwin on 06/02/19 15:01

The lowdown

Breast cancer is the most common type of cancer in the UK, with one person diagnosed every 10 minutes. Cancer Research UK predicts that one in eight women in the UK will develop breast cancer within their lifetimes, an increase of 50% over the last 25 years - making breast cancer market research a fast-growing fieldwork area. There are around 55,000 new cases of breast cancer reported in women in the UK every year, and although it’s much less common in men, there are still 390 male cases reported each year.

Read More

Topics: Therapy Area Information

Biosimilars: what are they and what do they mean for the NHS?

Posted by Adam Irwin on 31/01/19 12:11

 What are biosimilars?

A biological medicine is a type of treatment for long-term medical conditions such as rheumatoid arthritis, Crohn’s disease and psoriasis that’s given via a drip or an injection pen. A biosimilar medicine is simply a newer version of the original biological drug: as the name suggests, it’s highly similar to EMA-approved biological medicines in terms of safety, purity and potency, and it works in much the same way. There are no clinically meaningful differences, just minor differences in clinically inactive components being allowed, and they have to go through the same rigorous scientific assessments before becoming available on the market.

So how are they different to biological drugs? Well, instead of being created using chemical synthesis, biosimilars are synthesised from living organisms or their products, such as hormones, proteins yeast or bacteria. As a result, the molecules within the drug could vary slightly between different batches, which means research and development takes an average of about 10 years. In addition, biosimilars can only become available once a branded drug patent expires - and according to Pfizer, approximately 100 biologic products will lose patent or other protections by 2022, which means newer and cheaper biosimilar products will soon become available.

Read More

Topics: healthcare market research

Five reasons recruitment has been difficult for your medical fieldwork project

Posted by Adam Irwin on 28/01/19 09:45

Are you finding your medical fieldwork recruitment harder than you expected? Or perhaps you are unsure as to why your recruitment agency is taking so long to recruit your sample? Don’t worry - recruitment can be tricky at the best of times, and when it comes to sourcing high-quality respondents for healthcare market research, it can be even more frustrating. From busy HCPs to rare therapy areas, there’s so much to think about that sometimes when it comes to figuring where you might have tripped up, you can’t see for looking. And that’s exactly why we’ve written this blog! Read on and discover the five most common reasons why your medical fieldwork recruitment might be a little bit more difficult than you expected - and what you can do to fix it!

Read More

The history of the NHS

Posted by Adam Irwin on 24/01/19 16:13

Technically, the NHS officially began on 5th July 1948. Prior to this, local governments were responsible for running their hospitals, which meant that many hospitals weren’t adequately equipped, struggled to cater for people's needs and were inaccessible for the poor. It also meant the quality of care varied hugely from place to place, with rural areas having very limited access to hospitals and healthcare.

Read More

Topics: medical market research

The arrival of 5G and what it means for healthcare

Posted by Adam Irwin on 18/12/18 11:43

Thanks to apps, wearables and other connected devices, patients have never been in more control of their health. All of this new technology in the healthcare industry has huge benefits for stakeholders. So, if the industry wants to keep up with patient demands, it needs to reduce costs and improve efficiency - and next generation networks such as 5G are set to be a pivotal part of this transformation.

Read More

Topics: Healthcare Technology

From the patient's perspective… Narcolepsy

Posted by Adam Irwin on 11/12/18 16:32

Narcolepsy is a rare neurological condition that causes a person to suddenly fall asleep at inappropriate times. It means the brain is unable to regulate sleeping and waking patterns normally, resulting in excessive daytime sleepiness, sleep attacks where sufferers fall asleep suddenly and without warning, cataplexy (a temporary loss of muscle control resulting in weakness and possible collapse), sleep paralysis, and excessive dreaming and waking in the night. Although narcolepsy doesn't cause serious or long-term physical health problems, it can have a significant impact on daily life and be difficult to cope with emotionally. In this blog, we interview a patient who took part in a narcolepsy study, in order to humanise our patient journey research.

Read More

Topics: Patient Market Research

Subscribe to Email Updates

Recent Posts